Who are ramosetron, ondansetron, dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Granisetron and dexamethasone, Placebo, Palonosetron, Dexamethasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramosetron-ondansetron-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ramosetron, ondansetron, dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ramosetron, ondansetron, dexamethasone (ramosetron, ondansetron, dexamethasone) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist + corticosteroid combination. Area: Oncology / Supportive Care.

marketed 5-HT3 receptor antagonist + corticosteroid combination 5-HT3 receptor (ramosetron, ondansetron); glucocorticoid receptor (dexamethasone) Oncology / Supportive Care Small molecule Live · refreshed every 30 min

Target snapshot

ramosetron, ondansetron, dexamethasone (ramosetron, ondansetron, dexamethasone) — Government Medical College, Haldwani. This is a combination of three antiemetic agents: ramosetron and ondansetron block 5-HT3 receptors to prevent nausea/vomiting, while dexamethasone is a corticosteroid that reduces inflammation and enhances antiemetic effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ramosetron, ondansetron, dexamethasone TARGET	ramosetron, ondansetron, dexamethasone	Government Medical College, Haldwani	marketed	5-HT3 receptor antagonist + corticosteroid combination	5-HT3 receptor (ramosetron, ondansetron); glucocorticoid receptor (dexamethasone)
Granisetron and dexamethasone	Granisetron and dexamethasone	Guangxi Medical University	phase 3	5-HT3 receptor antagonist + corticosteroid combination	5-HT3 receptor (granisetron); glucocorticoid receptor (dexamethasone)
Placebo, Palonosetron, Dexamethasone	Placebo, Palonosetron, Dexamethasone	Azienda Ospedaliera di Perugia	phase 3	5-HT3 receptor antagonist + corticosteroid combination	5-HT3 receptor (palonosetron); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist + corticosteroid combination class)

Azienda Ospedaliera di Perugia · 1 drug in this class
Government Medical College, Haldwani · 1 drug in this class
Guangxi Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ramosetron, ondansetron, dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/ramosetron-ondansetron-dexamethasone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab